Cidara Therapeutics, Inc.
Cidara is developing targeted immunotherapies and antiviral drugs designed to save lives and improve the standard of care for patients facing serious diseases, including influenza. The company's proprietary platforms enable the development of novel drug conjugates and antivirals, with a focus on addressing unmet medical needs in infectious diseases and high-risk populations. Cidara's pipeline includes innovative therapies such as CD388, a long-acting antiviral with broad potential, and its efforts are supported by ongoing clinical trials, regulatory engagement, and strategic collaborations.
Industries
Nr. of Employees
medium (51-250)
Cidara Therapeutics, Inc.
San Diego, California, United States, North America
Products
CD388 — long‑acting antiviral drug–Fc conjugate (influenza)
A long‑acting drug–Fc conjugate that arrays multiple copies of a neuraminidase inhibitor on an engineered human antibody fragment to combine direct antiviral activity with Fc‑mediated immune engagement and extended systemic half‑life; evaluated in preclinical models and Phase 1–2 clinical studies including a large Phase 2b prophylaxis trial.
Conjugate discovery platform
A discovery and engineering platform for creating drug–Fc conjugates that couple small molecules or peptides to engineered Fc fragments to achieve target inhibition, immune engagement and extended half‑life across multiple therapeutic programs.
Rezafungin — antifungal candidate (developed and out‑licensed)
An echinocandin antifungal candidate advanced through preclinical and pivotal clinical development and subsequently progressed to regulatory submissions and commercialization via out‑licensing agreements.
CD388 — long‑acting antiviral drug–Fc conjugate (influenza)
A long‑acting drug–Fc conjugate that arrays multiple copies of a neuraminidase inhibitor on an engineered human antibody fragment to combine direct antiviral activity with Fc‑mediated immune engagement and extended systemic half‑life; evaluated in preclinical models and Phase 1–2 clinical studies including a large Phase 2b prophylaxis trial.
Conjugate discovery platform
A discovery and engineering platform for creating drug–Fc conjugates that couple small molecules or peptides to engineered Fc fragments to achieve target inhibition, immune engagement and extended half‑life across multiple therapeutic programs.
Rezafungin — antifungal candidate (developed and out‑licensed)
An echinocandin antifungal candidate advanced through preclinical and pivotal clinical development and subsequently progressed to regulatory submissions and commercialization via out‑licensing agreements.
Services
Collaborative discovery and development partnerships
Collaborative programs and licensing arrangements for discovery, IND‑enabling development, clinical trials and commercialization of conjugate therapeutic candidates.
CMC and IND‑enabling development via external CDMO collaborations
Coordination and execution of chemistry, manufacturing and controls activities to support IND filings and clinical supply using external manufacturing partners.
Large‑scale clinical trial management and execution
Operational management of large randomized, double‑blind, placebo‑controlled prophylaxis trials, including site management, blinded safety monitoring, data collection and interim analysis support.
Collaborative discovery and development partnerships
Collaborative programs and licensing arrangements for discovery, IND‑enabling development, clinical trials and commercialization of conjugate therapeutic candidates.
CMC and IND‑enabling development via external CDMO collaborations
Coordination and execution of chemistry, manufacturing and controls activities to support IND filings and clinical supply using external manufacturing partners.
Large‑scale clinical trial management and execution
Operational management of large randomized, double‑blind, placebo‑controlled prophylaxis trials, including site management, blinded safety monitoring, data collection and interim analysis support.
Expertise Areas
- Drug–Fc conjugate platform discovery and engineering
- Multispecific conjugate design and target selection
- Preclinical antiviral and immuno‑oncology pharmacology
- Clinical trial management for prevention and therapeutic programs (Phase 1–3, human challenge)
Key Technologies
- Drug–Fc conjugation chemistry
- Antibody Fc engineering
- Multispecific conjugate design
- Small‑molecule and peptide coupling to protein scaffolds